Integrated Diagnostics HoldingsLSE:IDHC +0.81%58 EBITDA Margin % is 22.09% as of Mar. 2026, which is 44% below its 10-year median of 39.73. GuruFocus rates LSE:IDHC with a GF Score™ of 58/100 and a GF Value™ of $0.57 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Integrated Diagnostics Holdings ranks better than 77.94% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Integrated Diagnostics Holdings EBITDA Margin % Related Terms
Integrated Diagnostics Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:IDHC vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Diagnostics Holdings EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Integrated Diagnostics Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings (LSE:IDHC) has a EBITDA Margin % of 22.09% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Integrated Diagnostics Holdings and its competitors. This is 44% below median its historical median of 39.73. Over the past decade, Integrated Diagnostics Holdings' EBITDA Margin % has ranged from 22.09 to 49.17. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #45 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 22.1%.
Is Integrated Diagnostics Holdings' EBITDA Margin % too high?
Integrated Diagnostics Holdings' current EBITDA Margin % of 22.09% is 44% below median its 10-year median of 39.73. Over the past 10 years, this metric has ranged from a low of 22.09 to a high of 49.17. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Integrated Diagnostics Holdings' value of 22.09% is 324.8% above this industry median. Based on the distribution chart, Integrated Diagnostics Holdings ranks #45 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #45 out of 204 companies for EBITDA Margin %. This places Integrated Diagnostics Holdings in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Integrated Diagnostics Holdings' value of 22.09% is 324.8% above this benchmark. Historically, Integrated Diagnostics Holdings' own EBITDA Margin % has ranged from 22.09 to 49.17 over the past decade. While the company's 10-year median is 39.73 vs. the industry median of 5.20, Integrated Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Diagnostics Holdings's current EBITDA Margin % of 22.09% is 324.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Integrated Diagnostics Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Diagnostics Holdings's current EBITDA Margin % is 22.09%, which is 44% below median its own 10-year median of 39.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.57, compared to a current price of $0.50 — trading 12.3% below its estimated fair value. The current EBITDA Margin % is 22.09%, which is 44% below median its 10-year median of 39.73 and 324.8% above the Medical Diagnostics & Research industry median of 5.20. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current EBITDA Margin % is 22.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued.
The current stock price of $0.50 is trading 12.3% below its estimated GF Value™ of $0.57.
GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.
Key valuation signals for LSE:IDHC:
EBITDA Margin %: 22.09% (44% below median its 10-year median of 39.73)
GF Value™: $0.57 vs. price of $0.50 (12.3% below fair value)
Industry Position: 324.8% above the Medical Diagnostics & Research median (#45 of 204)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings Business Description
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score
Get the complete analysis for LSE:IDHC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
